NCT06684158View on ClinicalTrials.gov

Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

March 1, 2027

Study Completion Date

December 1, 2027

Conditions
GC/GEJC
Interventions
DRUG

Mecapegfilgrastim

6 mg,HD d3,every 2weeks (Q2W)

DRUG

Adebrelimab

Adebrelimab：1200 mg，iv d1，every2 weeks (Q2W)

DRUG

Docetaxel

Docetaxel：50 mg/m2 iv gtt d1，every 2 weeks (Q2W)

DRUG

Oxaliplatin

Oxaliplatin ：85 mg/m2 iv gtt d1，every2 weeks (Q2W)

DRUG

5-Fluorouracil (5-FU)

5-FU ：2600 mg/m2 ，intravenous infusion， 24h ，d1，every 2 weeks (Q2W)

DRUG

Leucovorin (LV)

LV：200 mg/m2 iv gtt d1，every 2 weeks (Q2W)

Trial Locations (1)

210000

The First Affiliated Hospital with Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT06684158 - Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC | Biotech Hunter | Biotech Hunter